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Abstract
Background: In this phase II study, we evaluated the efficacy, toxicity, and patterns of failure of elective lymph
node irradiation (ENI) late course accelerated hyper-fractionated radiotherapy (LCAHRT) concurrently with
cisplatin-based chemotherapy (CHT) for esophageal squamous cell carcinoma (ESCC).
Methods: Patients with clinical stage II-IVa (T1-4N0-1M0 or M1a) ESCC were enrolled between 2004 and 2011.
Radiation therapy (RT) comprised two courses: The first course of radiation covered the primary and metastatic
regional tumors and high risk lymph nodal regions, given at 2 Gy per fraction for a dose of 40 Gy. In the second
course, LCAHRT was delivered to the boost volume twice a day for an additional 19.6 Gy in 7 treatment days, using
1.4 Gy per fraction. Two cycles of CHT were given at the beginning of RT.
Results: The median age and Karnofsky performance status were 63 years and 80, respectively. The American
Joint Committee on Cancer stage was II in 14 (20.6%) patients, III in 32 (47.1%), and IVa in 22 (32.3%). With a median
follow-up of 18.5 months, the overall survival at 1-, 3-, 5-year were 75.5%, 46.5%, 22.7% for whole group patients,
versus 78.6%, 49.4%, 39.9% for patients with stage II–III. The patterns of first failure from local recurrence, regional
failure, and distant metastasis were seen in 20.6%, 17.6%, and 19.1%, respectively. The most frequent acute
high-grade (≥ 3) toxicities were esophagitis and leucopenia, occurred in 26.4% and 32.4%.
Conclusions: ENI LCAHRT concurrently with CHT was appeared to be an effective regimen for ESCC patient with a
favorable and tolerated profile. Further observation with longer time and randomized phase III trial is currently
underway.
Trial registration: ChiCTR-TRC-09000568
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Background
Based on the results of the Radiation Therapy Oncol-
ogy Group (RTOG) phase III intergroup trial 85–01 and
95–04, the standard therapy for patients with localized
esophagus carcinoma selected for nonsurgical treatment
is radiation therapy (RT) plus concurrent chemotherapy
[1,2]. In RTOG 85–01, combined therapy significantly in-
creased 5-year overall survival (OS) to 26% (95% confi-
dence interval [CI], 15%–37%) compared with RT alone.
However, the incidence of local/regional failure and local/
regional persistence of disease was high up to 45.9% [1].
In an attempt to improve these results, RTOG 95–04 in-
creased radiation dose from 50.0 Gy to 64.8 Gy, however,
intensification of the radiation dose did not improve
local/regional control or survival [2]. Although the reason
for the lack of benefit using higher dose is unclear, a sig-
nificant prolongation of treatment time may have contrib-
uted, in part, to this result [2].
Several animal experiments and clinical investigations
have shown that accelerated proliferation of surviving
tumor clonogen during a standard schedule of RT is one
of the major reasons for treatment failure [3,4]. It is postu-
lated theoretically that a shortened irradiation course, still
keeping the total radiation dose, or increased dose of radi-
ation delivered in the late course of the treatment would
improve local control for esophageal carcinoma by over-
coming the deleterious effects of accelerated repopulation.
Clinical data from China [5] has shown late course acceler-
ated hyperfractionated radiotherapy (LCAHRT) improved
the 5-year OS (odds ratio [OR] = 2.93, 95% CI: 2.15–4.00,
p < 0.00001) and 5-year local control (OR = 3.96, 95%
CI: 2.91–5.38, p < 0.00001) than standard fractionated RT
in the localized esophageal carcinoma. Clinical investiga-
tion in nasopharyngeal [6,7] and lung carcinoma [8] also
displayed promising treatment outcome.
For esophageal squamous cell carcinoma (ESCC), lymph
nodal failure remains a major reason for poor prognosis.
Since the early 1980s, Japanese surgeons have practiced 3-
field regional lymph node dissection for esophageal cancer
and led to an improved survival [9,10]. It is thought that
prophylactic 3-field lymph node dissection improves the
survival rate by eliminating micrometastases and reducing
the regional lymph node recurrence rate. In accordance
with the concept of 3-field lymph node dissection in cu-
rative surgery, elective nodal irradiation (ENI) has been
adopted for definitive chemoradiotherapy in Japan. Al-
though, the benefit of ENI for ESCC remains controver-
sial, recently studies from Japan [11,12] have confirmed
ENI was effective for preventing regional and distant nodal
failure in patients with esophageal carcinoma undergoing
concurrent chemoradiation.
In randomized clinical trials, no consistent benefit was
seen for any specific chemotherapy regimens for locally
advanced ESCC. Cisplatin is one of the most active agents,
with a single agent response rate consistently in the range
of 20% or greater. Older agent 5-fluorouracil and newer
agents such as capecitabine, pemetrexed, were reported
effectiveness for locally advanced ESCC [13].
Based on above thinking, our institution had engaged in
clinical trials of ENI LCAHRT concurrently with cisplatin-
based chemotherapy (CHT) for ESCC since 2004. The re-
sults of our phase I studies [14,15] demonstrated that this
treatment scheme was feasible and tolerated, and the
treatment outcomes were encouraging. The results with
longer follow-up are now reported in the present study.
Methods
Patients population
Sixty-eight ESCC patients receiving ENI LCAHRTconcur-
rently with CHT were enrolled from January 2004 to No-
vember 2011. Enrollment was limited to clinical stage T1
to T4, N0/1, M0/1a of primary ESCC located at cervical-,
upper-, mid-, or distal-esophagus, according to American
Joint Committee (AJCC) tumor-node-metastasis (TNM)
system (2002). Eligibility and exclusion criteria were seen
below. The protocol was approved by our institutional re-
view board, and written informed consent was obtained
from all patients.
Eligibility criteria
The eligibility criteria were as following: (1) a Karnofsky
Performance Status (KPS) ≥ 70; (2) patients ≤ 75 years old;
(3) histologically confirmed ESCC with the previously un-
treated; (4) TNM stage for II, III, and IVa (cervical or celiac
node metastasis, not include organ metastasis according to
AJCC 2002); (5) weight loss ≤ 5%; (6) life expectancy ≥ 3
months; (7) absolute white blood cell count ≥ 4000/ml,
platelets ≥ 100,000/ml, total bilirubin level ≤ 1.5 mg/dl,
serum creatinine level ≤1.5 times the upper limit of nor-
mal, and aspartate/alanine aminotransferase levels ≤ 2.5
times the upper limit of normal. The TNM stage was
assessed by enhanced computed tomography (CT) and/or
combined with 18F-fluorodeoxyglucose position emission
tomography/computed tomography (18F-FDG PET/CT).
Exclusion criteria
Exclusion criteria were distant organ metastases, radio-
graphic or bronchoscopic evidence of esophageal per-
oration, the minimum lumen size less than 5 mm, and
some other serious underlying medical conditions such
as significant cardiac disease, uncontrolled diabetes, and
previous evidence of chemotherapy or RT.
Pretreatment evaluation
Pretreatment evaluation included a complete history and
physical examination, assessment of KPS and quality of life,
serum chemistry profile, complete blood cell count, chest
x-ray, ECG, endoscopy with biopsy. In order to exclude
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patients with distant organ metastases, pretreatment evalu-
ation also included upper gastrointestinal, chest, and ab-
dominal CT scan, bone scan with single photon emission
computed tomography, magnetic resonance imaging scan
of the brain and neck, or a whole body 18F-FDG PET/CT
scan.
Chemoradiotherapy
Details of LCAHRT were published previously [14,15].
Briefly, the radiation was carried out by 6 MV or 15 MV
X-ray using a two-course irradiation schedule: the first
course of radiation covered the primary tumors and
metastatic regional lymph node(s) and high risk lymph
nodal regions (HRLNR), given at 2 Gy per fraction, 5
days a week for a dose of 40 Gy in 20 fractions; the sec-
ond course of radiation was delivered to the boost vol-
ume for an additional dose of 19.6 Gy twice a day in 14
fractions within 7 days using 1.4 Gy per fraction with a 6
h minimal interval between fractions. The total dose de-
livered of the two-course irradiation would be 59.6 Gy/
34 fractions in 5.4 weeks. Accelerated radiation (1.4 Gy
per fraction) was used in this protocol in an effort to
prevent the late toxicities of mormal tissues. The gross
tumor volume included primary cancer (GTVp) and
metastatic lymph nodes (GTVn). The planning target
volume (PTV) of the first course (PTV1) was defined as
GTVp adding a 5 cm margin superiorly and inferiorly
and 1 cm laterally, and GTVn with a 0.8 cm margin, as
well as HRLNR adding a 0.8 cm margin. The PTV of the
second course (PTV2) was shortened along the superior
and inferior ends of GTVp with 3 cm margins, whereas
the width of fields remained 1 cm, as well as GTVn
adding a 0.8 cm margin. However, the HRLNR were
spared.
The chemotherapeutic regimens in present study
consisted of cisplatin 25 mg/m2/day i.v. on days 1–3 plus
5-FU 600 mg/m2/24h by continuous infusion on days 1–5
or plus capecitabine 1000 mg twice daily with a 12 h
interval on days1–14 or plus pemetrexed 400 mg/m2 on
days 1 of a 21-day cycle [14,15]. Two cycles of concurrent
chemotherapy were administrated during the process of
RT. The choice of chemotherapy regimens for this study
was dependent on the economic situation of patients and
their voluntary.
Treatment-related toxicity assessment and follow-up
Treatment-related toxicity assessment was performed at
least weekly during treatment, 4 weeks after completion
of therapy, every 3 months for 2 years, and every 6
months thereafter using the National Cancer Institute
Common Toxicity Criteria (version 3.0). A full history
and physical examination, as well as repeat blood work
were recorded at these visits. A Spiral CT-scans of the
neck, chest, and abdominal were obtained at every follow-
up examination to monitor morphological changes in nor-
mal tissue structure with respect to radiation-induced tox-
icity and to evaluate the status of locoregional and distant
disease.
End points and statistics
The primary end point for this study was OS. Survival was
measured from the beginning of RT until the last
follow-up or death. The secondary end points were
treatment-related toxicity, and patterns of failure, included
local recurrence (primary tumor), regional failure (lymph
nodes), locoregional failure (local recurrence plus regional
failure) and distant metastasis. The survival analysis was
performed by the actuarial Kaplan-Meier method, and dif-
ferences between the curves were analyzed by using the
log-rank test. Analysis of patterns of failure was performed
by using crude calculations.
Results
Patient-, tumor- and treatment-related characteristics
Sixty-eight patients (male/female 58/10; cervical/upper/
mid/lower 8/24/27/9) were enrolled in the study. All pa-
tients were followed until death or the time of analysis.
The age ranged from 40 to 75 years (median, 63 years).
The KPS was evaluated as 70–100 (median, 80). Four-
teen patients had stage II, 32 stage III, and 22 stage IVa.
The distribution of TNM stage for enrolled patients
from 2004 to 2011 was displayed in Figure 1. Patient-,
tumor- and treatment-related characteristics were sum-
marized in Table 1.
Survival
The median survival was 34.4 months (95% CI 19.1–
49.6 months) for whole group patients, and the 1-, 3-, 5-
year OS were 75.5%, 46.5%, 22.7%, respectively (Figure 2).
Figure 1 TNM stage distribution in 68 patients. The American
Joint Committee TNM stage was II in 14 (20.6%) patients, III in 32
(47.1%), and IVa in 22 (32.3%), respectively.
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For patients with stage II–III, the 1-, 3-, and 5-year OS were
78.6%, 49.4%, and 39.9%, respectively, versus 68.3%, 41.0%,
and 15.4% for IVa patients, respectively. The Kaplan-Meier
survival curve was presented in Figure 3. The difference
in OS among patients with different clinical stages was
not statistically significant (Chi-square=0.180, p=0.671).
Similar result was also observed among patients receiv-
ing different chemotherapy regimens (Chi-square=0.159,
p=0.690) (Figure 4).
Patterns of failure
The crude patterns of failure were listed in Table 2. The
incidence of any local recurrence, regional failure, and
distant metastasis were 20.6%, 17.6%, and 19.1%, respect-
ively. About twenty-nine percent (20/68) of the patients
had local or/and regional disease presenting as the first
failure, distant metastases as the first failure occurred in
13 patients. The sites of distant metastases were: liver (4),
bone (2), lungs (1), pleura (1), brain (1), and multi-organs
(1). Moreover, another three patients developed distant
lymph node metastases containing cervical (1), celiac (1),
and retroperitoneal (1) parts.
Toxicity
The incidence of grade 3 or higher acute radiation tox-
icity was seen in Table 3. Esophagitis in Grade 3 was
Table 1 Patient-, tumor- and treatment-related
characteristics
Characteristics No. %








KPS 70-80 52 76.5
KPS 90-100 16 23.5
AJCC TNM stage
Stage IIa 10 14.7
Stage IIb 4 5.9
Stage III 32 47.1













* Others treated with cisplatin plus vinorelbineis (1), gemcitabine (1), and
docetaxel (2).
Figure 2 Kaplan-Meier curve of overall survival (OS) for
whole group patients treated with late course accelerated
hyper-fractionated radiotherapy plus concurrent chemotherapy.
With a median follow-up of 18.5 months, the median survival was
34.4 months (95% confidence interval: 19.1–49.6 months), and the
1-, 3-, 5-year OS were 75.5%, 46.5%, 22.7%, respectively.
Figure 3 Kaplan-Meier curves of overall survival (OS) were
compared in patients with TNM stage II-III and IVa. For patients
with stage II–III, the 1-, 3-, and 5-year OS were 78.6%, 49.4%, and
39.9%, respectively, versus 68.3%, 41.0%, and 15.4% for IVa patients,
respectively, however, no statistically significant difference was
observed in our limited sample size (p=0.671).
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recorded in 18 patients (26.4%). Leucopenia in grade 3–4
was recorded in 22 patients (32.4%). No patients de-
veloped grade 3 and worse lung toxicity (pneumonitis).
Treatment-related high-grade (≥ 3) skin injury and gastro-
intestinal reaction were observed in 1 and 2 patients,
respectively. One patient developed esophageal stenosis
in grade 3, and another one had pulmonary fibrosis in
grade 3. However, five patients died of late complica-
tions as displayed in Table 4, including gastrointestinal
hemorrhage (4.4%) and esophagus fistula (2.9%).
Discussion
ESCC remains one of the most lethal carcinomas in
China. The poor survival is mainly related to the ad-
vanced stages at diagnosis. The optimal management for
locally advanced disease remains controversial. Surgery
or RT alone is associated with a poor survival, usually
less than 10% at 5 years [16]. Randomized studies [1,2]
have demonstrated the survival advantage of concurrent
chemoradiotherapy compared with RT alone for patients
with squamous cell or adenocarcinoma of the esophagus.
Although concurrently administered chemotherapy acts
as a promoter of the locoregional effects of RT, the
locoregional control remains unsatisfactory in RTOG
85–01 trail [1]. Dose escalation trial by RTOG 94–05
failed to improve the locoregional control as well [2]. It
may thus be concluded that by simply increasing the
local radiation dose cannot easily convert to survival
benefits for esophageal carcinoma patients. Therefore,
many efforts have been made to explore the more rea-
sonable treatment schedules based on this thinking and
understanding to radiobiology.
From last two decades, a further increase in local-
regional tumor control may be expected by augmenting
radiation effects by altering fractionation schedule, be-
cause rapid tumor clonogen repopulation during treat-
ment seems to be a cause of poor prognosis for cancer
patients. One phase II study from Japan showed a promis-
ing result for ESCC patients treated with accelerated
hyperfractionated RT plus 5-fluorouracil/cisplatin chemo-
therapy [17]. In China, Shi and their teams [18] initiated
the study of LCAHRT for ESCC treatment, and yielded
very encouraging results. Comparing with conventional
fractionation (CF), the 5-year survival (34% versus 15%)
and local control (55% versus 21%) were markedly im-
proved with the LCAHRT regime. Henceforth, unremit-
ting results from randomized and retrospective trials came
out [19-23]. Recently, three independent meta-analysis
from China strengthened the evidence of therapeutically
beneficial of LCAHRT compared with CF for esophageal
carcinoma [5,24,25].
Because of unique geographical and pathologic fea-
tures of esophageal carcinomas in China, furthermore,
esophageal carcinomas tend to spread axially to region-
al lymphatics, producing morbidity and mortality from
locoregional effects [1]. Based on the previous studies
[9,10], we supposed that elective HRLNR irradiation might
be associated with lower nodal failure in advanced stage
ESCC, and this hypothesis was supported by recent stud-
ies from Asian [11,12,26]. From another point of view,
considering of high incidence of nodal failure in combined
modality therapy, chemotherapy seems to play a limited
role in preventing locoregional or distant nodal failure.
Omitting ENI may be not reasonable for locally advanced
stage ESCC patients, especially if the primary tumor lo-
cated in lymphatic-rich regions [27] and PET/CT could
not be incorporated in the planning of radiotherapy [28].
Previous study designed by Zhao et al. [22] enrolled 54
cases of local advanced stage ESCC with clinical stage
T1-4N0-1M0 treated with LCAHRT (41.4Gy/23 fractions
followed by 27Gy/18 fractions with 1.5Gy per fraction,
twice a day) and 2 cycles of concurrent chemotherapy
with cisplatin (25 mg/m2/day days 1–3) plus 5-FU (600
Figure 4 Kaplan-Meier curves of overall survival (OS) were
compared in patients receiving different chemotherapy
regimens. Our data did not show statistically significant difference
in OS rates between the three groups (p=0.690).
Table 2 Patterns of failure
Patterns of failure No. %
Local recurrence only 8 11.8
Regional failure only 6 8.8
Locoregional failure 4 5.9
Distant lymph node metastases only 3 4.4
Distant organ metastasis only 8 11.8
Locoregional failure plus distant metastasis 2 2.9
Dead of complication 5 7.4
Other diseases 4 5.9
Unknown 3 4.4
Wang et al. Radiation Oncology 2013, 8:108 Page 5 of 9
http://www.ro-journal.com/content/8/1/108
mg/m2/day days 1–3). And they reported the median
survival was 30.8 months (95%CI, 17.6–44.1 months),
Survival rates at 1, 3, and 5 years were 67%, 44%, and
40%, respectively. Twenty-six percent (14/54) of patients
had locoregional disease presenting as the first failure,
and distant metastases as the first failure occurred in 24%
(13/54). In our study, 40Gy/20 fractions delivered to pri-
mary and metastatic regional tumor(s) and HRLNR, and
additional 19.6Gy/14 fractions in 1.4Gy per fraction, twice
a day, were given to the boost volume. Cisplatin-based
chemotherapy concurrently administered during the RT
course. Our regimen improved median survival time from
30.8 to 34.4 months, and the OS at 1-, 3-year improved
from 67%, 44% to 75.5%, 46.5%, respectively. However,
this trend was not observed at 5-year (40% vs. 22.7%). It
should be noticed that approximately 32.3% of the popu-
lation consisted of stage IVa cases, and 46% of eligible pa-
tients were enrolled between 2010 and 2011 (Figure 1) in
our study, which may partially explain the relatively poor
5-year OS. By subgroup analysis, for patients with stage
II–III, the 5-year OS reached to 39.9%, which was similar
to the results of Zhao et al. [22]. Despite the study cohort
consisted of a high proportion of patients with stage IVa,
this regimen was associated with only twenty-nine per-
cent of local or/and regional failure and nineteen percent
of distant metastases. Previous studies (Table 5) focusing
on LCAHRT regimen reported the patterns of failure
from local/locoregional failure and distant metastasis
were 12.5–41.8% and 15.4–34.9%, respectively [18-23] in
patients with TNM stage limited to I–III.
Regarding tolerance in our study, high-grade (≥3) acute
esophagitis and leucopenia were seen in 26.4% and 32.4%
of patients, respectively. Similar findings were reported
by Zhao et al. [22]. The higher rates of acute toxicities
may be related to this treatment scheme. Our approach
allowed us to avoid potential micrometastasis of lym-
phatics, nevertheless, it was gained at the expense of early
toxicities. Therefore, how to minimize the damage to the
sensitive normal tissues within irradiated fields without
sparing cancer is a big challenge. Recent innovation of RT
technology has made it possible to use sophisticated rota-
tional intensity-modulated RT. This can deliver intensified
radiation doses to the tumor while minimizing the doses
to the normal tissues [29]. Acceleration of radiation treat-
ment involves the delivery of the target dose in less time,
and is analogous to the concept of dose-intensity in the
delivery of cytotoxic chemotherapy. In order to prevent
late toxicity, we reduced the dosage of per fraction (1.4Gy
per fraction twice day). The interval between daily frac-
tions (typically ≥ 6 hours) provides normal tissues with
time to repair sublethal radiation damage, which may be
responsible for the lower rate of late lung toxicity in our
study. Notably, treatment-related upper-gastrointestinal
hemorrhage (4.4%) and esophagus-tracheal fistula (2.9%)
were relatively higher, which should be paid much atten-
tion. Although the reason for the higher incidence of such
complications was unknown, we suspected that it might
be association with advanced T stage in our cohort of
patients.
Table 3 Treatment-related toxicity
Treatment-related toxicity Grade 0-1 Grade 2 Grade 3 Grade 4 Grade 5
Acute toxicity
Lung 67 (98.5%) 1 (1.5%) 0 0 0
Esophagus 29 (42.7%) 21 (30.9%) 18 (26.4%) 0 0
Skin 67 (98.5%) 0 1 (1.5%) 0 0
Hematologic
Hemoglobin 60 (88.2%) 3 (4.4%) 4 (5.9%) 1 (1.5%) 0
Leucopenia 20 (29.4%) 26 (38.2%) 20 (29.4%) 2 (2.9%) 0
Neutropenia 53 (77.9%) 3 (4.4%) 12 (17.7%) 0 0
Thrombocytopenia 48 (70.6%) 13 (19.1%) 5 (7.4%) 2 (2.9%) 0
Gastrointestinal 57 (83.8%) 9 (13.2%) 2 (2.9%) 0 0
Late toxicity
Lung 64 (94.1%) 3 (4.4%) 1 (1.5%) 0 0
Esophagus 61 (89.7%) 4 (5.9%) 1 (1.5%) 0 2 (2.9%)
Heart 66 (97.1%) 2 (2.9%) 0 0 0
Table 4 Treatment-related complications
Complications No %
Upper-gastrointestinal hemorrhage 3 4.4
Esophagus-tracheal fistula 2 2.9
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Table 5 Survival and toxicities of patients undergoing late course accelerated hyper-fractionated radiotherapy for esophageal squamous cell carcinoma
First author Study No. of patients TNM stage Treatment scheme Overall survival Locol control Treatment failure Toxicity (Grade≥3)
Shi XH [18] Prospective 43 T1-4N0-1M0 41.4Gy/23fx followed by 27Gy/18fx
with 1.5Gy, bid
5-year 34% 5-year 55% LR 41.8% (18/43) PI 27.9% (12/43)
DM 18.6% (8/43) EI 34.9% (15/43)
Wang Y [19] Prospective 52 T1-4N0-1M0 41.4Gy/23fx followed by 27Gy/18fx
with 1.5Gy,bid
1-year 80.0% 1-year 80.7% LRF 13.5% (7/52) PI 3.8% (2/52)
EI 9.6% (5/52)
ES 1.9 % (1/52)3-year 41.2% 3-year 57.1% DM 15.4% (8/52)
PF 0% (0/48)
EH 3.8% (2/52)
Zhao KL [20] Retrospective 56 T1-2N0M0 41.4Gy/23fx followed by 27Gy/18fx
with 1.5Gy, bid
1-year 90.9% 1-year 90.9% LR 12.5% (7/56) PI 5.4 % (3/56)
3-year 54.6% 3-year 84.5% EI 10.7 % (6/56)DM 21.4% (12/56)
ES 1.8 % (/56)
5-year 47.8 % 5-year 84.5 % PF 1.8 % (/56)
Zhao KL [21] Retrospective 201 T1-4N0-1M0 41.4Gy/23fx followed by 27Gy/18fx
with 1.5Gy, bid
1-year 73%, 1-year 77% LRF 38.4% (77/201) EI 15.4% (31/201)
PI 7.0% (14/201)
3-year 34%, 3-year 58% EF 0.5% (1/201)DM 34.9% (70/201)
5-year 26% 5-year 56%
Zhao KL [22] Prospective 54 T1-4N0-1M0 41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy,
bid Plus ≥2 cycles of CHT with cisplatin+5-FU
1-year 67%, 1-year 84% LRF 25.9% (14/54) EI 24.1% (13/54)
PI 5.5% (3/54)
3-year 44%, 3-year 74% PF 14.8% (8/54)
5-year 40% 5-year 67% DM 24% (13/54) ES 3.7% (2/54)
Wang JH [23] Prospective 48 T1-4N0-1M0 40Gy/20fx followed by 21–27 Gy/14-18fx
with 1.5Gy, bid
1-year 79.2% 1-year 81.3% LR 35.4% (17/48) PI 33.33% (16/48)
EI 27.1% (13/48)
ES 14.6% (7/48)3-year 43.8% 3-year 50.0% DM 16.7% (8/48)
PF 0% (0/48)
Note: distant metastasis–DM; local recurrence–LR; locoregional failure–LRF; esophagitis–EI; pneumonitis–PI; pulmonary fibrosis–PF; esophageal stenosis–ES; esophageal hemorrhage–EH; esophagus fistula–EF; fractions–

















Several strengths and limitations should be noted. This
was a single center study with a relatively small sample
size, which may limit the generalizability of our findings.
This study cohort consisted of a higher proportion of
stage IVa who had worse prognosis. Moreover, a variety of
cisplatin-based chemotherapy regimens were enrolled, al-
though OS rate was not associated with combined regi-
mens. The chemotherapy agents are usually 5-fluorouracil
and cisplatin. Recently, capecitabine and pemetrexed have
been introduced in phase I and II trials and the prelimin-
ary results are promising [13]. Therefore, how to best
combine chemotherapy and accelerated radiotherapy regi-
mens to maximize local control and survival is an import-
ant question. Further trials and observation confirming
the efficiency of LCAHRT concurrently with these chemo-
therapy regimens are still needed. At last, this accelerated
radiation scheme is broadly used as a standard treatment
for locally advanced ESCC and non-small cell lung cancer
in China, however, has not met with widespread clinical
acceptance in the United States or Europe probably be-
cause of higher acute toxicity, and the use of twice frac-
tions per day.
In conclusion, this phase II study with limited number
of patients demonstrated that ENI LCAHRT concur-
rently with CHT was generally tolerated, and the treat-
ment outcome was satisfactory. Although these results
by this interim analysis were not sufficient to confirm
the impact on ESCC treatment with this regimen, the re-
sults in our cohort patients with a higher proportion of
advanced stage were compared favorably with those of
previous studies. Further observation with longer time
follow up and randomized phase III trial is currently
underway.
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